

Assessing Haemoglobin Concentration and Red Cell Morphology in Stored Blood Units

ABSTRACT

Aims: This study assessed and compared the haemoglobin concentration and red cell morphological changes in stored blood units at the Tamale Teaching Hospital located in the Northern Region of Ghana.

Methods: This is experimental research conducted from November, 2019 to June, 2020. Thirty blood samples were collected (450ml) from voluntary donors at the blood bank unit of the Tamale Teaching Hospital for this study. The samples were collected into blood bags that contained CPDA-1 preservative and stored at 2-6°C for thirty-five days. The haemoglobin concentration and red cell morphology of the samples were assessed at collection and every seventh day (weekly) till the thirty fifth day using the URIT-15 hemoglobin meter and Leishman-stained thin films.

Results: Microscopic examination of Leishman-stained thin films indicated significant degenerative changes in red cell morphology as the storage duration increased. The red cell morphology showed changes from normocytic cells through to echinocytes, spherocytocytes and spherocytes. ANOVA with a Greenhouse-Geisser correction revealed the mean of haemoglobin (Hb) values as statistically significant between storage days (day 0, 7,14, 21, 28 and 35) ($F(3.264, 94.657) = 18.967, p < 0.05$). Post hoc analysis revealed significant differences between storage days. There were statistically significant differences in haemoglobin concentrations between days 7 and 35 of storage, as well as days 21 and 35 and between days 28 and 35 [$p < 0.05$]. Precisely, at day 0 ($12.0633 \pm 1.10812, M \pm SD$) the haemoglobin concentrations were higher than the other storage days. **Conclusion:** There is gradual reduction in haemoglobin concentration as well as gradual significant degeneration in red cell morphology as storage age of blood increased. The study therefore recommends that, blood with less storage duration should be preferred for transfusion for best therapeutic improvement.

Keywords: stored Blood, CPDA-1, haemoglobin, lesion, morphology, red blood cell, storage and transfusion.

INTRODUCTION

Allogenic transfusion of blood or any of its components for therapeutic reasons is a relatively common treatment modality employed in modern-day healthcare in dealing with diverse medical conditions, thus making blood the most frequently demanded and applied medicine. Transfusion aims not only to provide blood but ensure it is safe and efficacious post transfusion. However, despite the major scientific breakthroughs acclaimed over the years, there is yet to be produced any substitute for blood in terms of its therapeutic value, thus making blood and many of its components one of the most frequently demanded and applied medicine globally [1]. It has been reported that more than a half million women die each year from severe bleeding as a result of childbirth and pregnancy related complications [2]. This underscores the need for transfusion to prevent some of these mortalities [3]. Among 46 member states of the WHO Africa region with total population of 836,969,536, the demand for blood transfusion is over eight (8) million units per year [4]. Although being the most frequently applied medicine worldwide, it remains one of the major public health concerns [5]. Storage and preservation of blood is therefore required to ensure readily available safe blood supply for transfusion. However, despite the efforts made, blood tends to undergo certain biochemical, molecular and morphological changes termed "storage lesions" during storage which can contribute to post transfusion complexities in some medical conditions.

Red Blood Cells (RBCs), are the most abundant cells among the 3 types of blood cells (Red blood cells, White blood cells and Platelet). The key role of RBC is delivery of oxygen to tissues in the body. The delivery of the oxygen is facilitated by an iron containing metalloprotein called haemoglobin found in red cells. The lifespan of RBC is about 120 days before it is aimed for destruction by the reticuloendothelial

32 system, usually in the spleen and liver. It is understood that the ageing of RBCs is prone to entail many
33 structural changes on the cell surface, which finally triggers macrophage recognition and phagocytosis
34 [6].

35 Blood is collected into blood bags. The blood bags are sterile and pyrogen-free. The labels indicate the
36 type, quantity of anticoagulant and the quantity of blood it can contain. Normally, blood is collected into
37 either a 450mL or 500mL blood bag, which contains 63 mL of anticoagulant [1]. The type of anticoagulant
38 or additive in the blood bag determines the shelf life of the RBCs during storage. The most common
39 anticoagulant used is the Citrate Phosphate Dextrose Adenine (CPDA-1), which has a storage time of 35
40 days. The essence of the appropriate storage is to counteract damages to the metabolic machinery and
41 cell membrane of the red cells in order to maintain viability of the red cells and functional efficacy post-
42 transfusion [7].

43 Many studies have shown that a group of disorders called 'storage lesion' affect red cells during storage
44 [8-11]. Storage lesions are morphological and metabolic anomalies which affect red cells during storage,
45 and these are associated with reduced survival of cells post-transfusion, increasing the risk of transfusion
46 related mortality, morbidity and these lesions significantly increase with increasing duration of storage
47 time [12, 13].

48 The storage medium contains dextrose which provides glucose for glycolysis in stored blood. The
49 medium also provides ATP, 2,3DPG and NADH needed to maintain red blood cells functionality and
50 viability. Glycolysis results in the accumulation of byproducts as storage duration increases. Lactic acids
51 in the supernatant result in acidosis which in turn inhibits glycolysis through a negative feedback
52 mechanism leading to the reduction in ATP, 2,3DPG and NADH [14]. The reduction in metabolic activity
53 results in depletion of ATP, 2,3DPG [15]. The progressive accumulation of byproducts of glycolysis and
54 lactic acid result in decreased pH. These changes affect red cell membrane and shape, thus leading to
55 loss of deformability with the formation of reversible echinocytes, irreversible spherocytes and
56 spherocytes [16].

57 This study aimed to assess the haemoglobin concentrations and red cell morphologies before storage
58 and during storage at a regular interval of seven days till the 35th day in order to ascertain the association
59 between storage time, haemoglobin level and red cell morphologies. This study revealed the association
60 between storage duration, haemoglobin concentration and red cell morphologies to help develop
61 strategies or guidelines for prescription of blood.

62 **MATERIAL AND METHODS**

63 **Study Design**

64 An experimental research design was used to evaluate and comparatively assess the relationship
65 between haemoglobin concentrations, red cell morphologies and storage duration at the blood bank of
66 the Tamale Teaching Hospital (TTH).

67 **Inclusion Criteria**

68 Healthy participants between the ages of 18 to 65 years were enrolled for the study. Healthy participants
69 in this context are those individuals that passed the blood donor selection criteria; healthy donor
70 appearance, not showing any sign of febrile and persistent coughing, weight not less than 50 Kg and
71 body temperature not more than 37.6 °C.

72 **Exclusion Criteria**

73 Subjects out of the 18 to 65 age range were excluded from the study. Blood from individuals who did not
74 pass the blood donor selection criteria were also excluded from the study.

75 **Sample Collection and Processing**

76 After obtaining informed consent from the participants, they were subjected to the donor selection criteria,
77 donor interview, donor health and risk assessments, and pre-donation counselling. Participants were
78 physically examined and haemoglobin concentration checked using the copper sulphate method [17].
79
80
81
82
83

84
85 Successful participants were prepared for phlebotomy following all quality control and safety procedures.
86 Exactly 450ml of blood was collected from each participant into a blood bag containing Citrate-Phosphate
87 Dextrose Adenine (CPDA-1) anticoagulant. The blood units were labelled with the donor identification
88 number, date of collection and expiration date. Aliquot of 3ml of the gently mixed blood was collected into
89 a plain tube and haemoglobin was measured and thin film for red cell morphology was prepared for day
90 0. The blood units were stored in a refrigerator at 2-6°C.

91 92 **Haemoglobin Measurement**

93 Aliquot (3 ml) of whole blood samples was drawn from each unit of blood into plain tubes. Haemoglobin
94 concentrations were measured using URIT-15 haemoglobin meter manufactured by URIT medical
95 electronic company limited.

96 97 **Preparation of Thin Films**

98 Clean dried slides were labelled with the participant's identification number. Micropipette was used to
99 transfer 20µL of the whole blood to the center of the slide and another clean slide with smooth, flat edge
100 used as a spreader. The spreader was placed in front of the blood at an angle of 30° - 45° allowing the
101 drop to spread to the contact line of the two slides and the spreader pushed forward rapidly and gently.
102 The slides were allowed to air-dry and then fixed in absolute methanol and allowed to air-dry completely
103 before staining with Leishman and morphology observed using light microscopy.

104 105 **Data Analysis**

106 Data for haemoglobin concentration was analyzed using Statistical Package for Social Sciences (SPSS)
107 software. Data entry was cross-checked individually and compared. One-way Repeated means Analysis
108 of Variance (ANOVA) was used to determine any statistical significance between storage periods (Day: 0,
109 7, 14, 21, 28 and 35). P-value of ≤ 0.05 was considered as statistically significant.

110 111 **RESULTS**

112 The mean haemoglobin concentration (g/dl) decreased gradually from 12.06 ± 1.11 g/dl at collection day
113 0 to 8.96 ± 2.09 g/dl at storage day 35 (Table 1). In this study, blood stored for one week (day 7) showed
114 no significant reduction in haemoglobin concentration when compared with whole blood stored for 14
115 days (Table 3). Similarly, blood stored for 14 days showed no significant declined in haemoglobin
116 concentrations as compared with blood stored for 21 days and 28 days. Blood stored for 21 days showed
117 no significant decrease in haemoglobin concentration when compared with blood stored for 28 days
118 (Table 3).

119
120 One-way Analysis of Variance (ANOVA) with a Greenhouse-Geisser correction showed that the mean
121 haemoglobin (Hb) is significantly different between storage days (day 0, 7, 14, 21, 28 and 35) ($F 27.459$, p
122 $= .000$) (table 2). Post hoc analysis revealed that the mean Hb is significantly higher on day 0; $M = 12.$
123 06 g/dL, $SD = 1.11$ (Tables 1 and 3). Hb was significantly higher on day 7 compared with day 35 of
124 storage. Similarly, Hb was significantly higher on day 21 compared with days 28 and 35 (Table 3).

125 **Table 1: General Characteristics**

	Samples	Minimum	Maximum	Mean	Std. Deviation
Age of participants (years)	30	18	40	25.17	6.01
Hb (g/dL) of Day 0 of storage	30	8.80	13.60	12.06	1.11
Hb (g/dL) of Day 7 of storage	30	5.70	17.50	10.57	2.10
Hb (g/dL) of Day 14 of storage	30	6.20	16.50	10.01	2.07
Hb (g/dL) of Day 21 of storage	30	5.60	14.90	9.69	2.12
Hb (g/dL) of Day 28 of storage	30	5.30	17.70	9.52	2.31
Hb (g/dL) of Day 35 of storage	30	5.40	15.20	8.96	2.09

126 *Hb: Haemoglobin, Std. Deviation: Standard Deviation

127

128 Table 2: Results of the ANOVA for within subject effects for haemoglobin (Hb)

Source		Type III Sum of Squares	Df	Mean Square	F	Sig.
Day	Sphericity Assumed	176.554	5	35.311	27.459	.000
	Greenhouse-Geisser	176.554	2.788	63.322	27.459	.000
	Huynh-Feldt	176.554	3.115	56.681	27.459	.000
	Lower-bound	176.554	1.000	176.554	27.459	.000
Error (Day)	Sphericity Assumed	186.466	145	1.286		
	Greenhouse-Geisser	186.466	80.858	2.306		
	Huynh-Feldt	186.466	90.331	2.064		
	Lower-bound	186.466	29.000	6.430		

129 *df: Degree of freedom, F: F-Statistic or Ratio, Sig: Significance level at .05

130


131 Table 3: Post hoc comparisons of haemoglobin concentrations (g/dl) between storage days

(I) Day	(J) Day	Mean Difference (I-J)	Std. Error	Sig.
0	7	1.493	.352	.003
	14	2.057	.401	.000
	21	2.373	.388	.000
	28	2.547	.429	.000
	35	3.103	.385	.000
7	0	-1.493	.352	.003
	14	.563	.241	.394
	21	.880	.210	.004
	28	1.053	.239	.002
	35	1.610	.234	.000
14	0	-2.057	.401	.000
	7	-.563	.241	.394
	21	.317	.253	1.000
	28	.490	.268	1.000
	35	1.047	.265	.007
21	0	-2.373	.388	.000
	7	-.880	.210	.004

	14	-.317	.253	1.000
	28	.173	.219	1.000
	35	.730	.165	.002
28	0	-2.547	.429	.000
	7	-1.053	.239	.002
	14	-.490	.268	1.000
	21	-.173	.219	1.000
	35	.557	.154	.017
35	0	-3.103	.385	.000
	7	-1.610	.234	.000
	14	-1.047	.265	.007
	21	-.730	.165	.002
	28	-.557	.154	.017

132

- *The mean difference is significant at the .05 level*



133

134 **Figure 1: Profile plot of estimated marginal means of haemoglobin**

135

136 Assessment of RBC morphology at collection day 0 generally showed normocytic normochromic cells
 137 with no notable changes in the shape of the RBCs. Storage day 7 generally showed normocytic
 138 normochromic cells with few echinocytes (Figure 2). Morphological assessment of RBCs on the various
 139 storage days (14th, 28th and 35th), revealed significant degenerative changes. The RBCs gradually
 140 changed from normocytes through echinocytes, spherocytes and spherocytosis (Figure 2). Day 35 of
 141 storage revealed marked reduction of normocytes with marked spherocytosis and spherocytosis.

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

MORPHOLOGICAL ASSESSMENT OF RED BLOOD CELLS


158 Microscopic examination of Leishman-stained thin films suggested significant degenerative changes in
159 red cell morphology as the storage duration increased. The red cell morphology showed changes from
160 normocytic through to echinocytes, spherocytes and spherocytes.
161

162

Day 0

Day 7

163



164

165

166

167



168

Day 14

Day 21

169

170



171

172

173

174



175

Day 28

Day 35

176

177



178

179

180

181

182

Figure 2: Red cell morphology at the assessment days

Photomicrographs of representative slides showing the morphological abnormalities on the assessment days; day 0, 7, 14, 21, 28 and 35. Keys: I: Normocytic cell, II: Echinocytic cell, III: Spherocytic cell, IV: Spherocytic cell

DISCUSSION

The 30 voluntary blood donors in good health and within the ages of 18 to 65 years recruited into this study is in conformity with recommendations from the World Health Organization for allowable safe age range for blood donation [18, 19]. The minimum, mean and maximum ages of 18, 25.17 and 40 years documented among donors respectively in this study is similar to the findings of Antwi-Baffour [20] which recruited 10 healthy donors between the ages of 20 to 52 years. Participants younger than 18 years were excluded in order to reduce the possibility of adverse effect which is common amongst younger people [21, 22]. Younger adolescents also have an increased requirement for iron for their own growth and development, especially in adolescent menstruating females [23-25]. All the study participants were males, many of the female blood donors did not meet the criteria for blood donation because many of the females had haemoglobin concentration below recommended levels. These results are similar to those reported by Pavord, Myers [26], Salvin, Pasricha [27].

The decrease in haemoglobin as storage time increased could possibly be due to haemolysis of red blood cells in the blood bag. Blood undergoes gradual haemolysis in the suspending medium due to prolonged contact with plasma resulting in release of haemoglobin into the plasma, increasing the plasma haemoglobin while reducing the total haemoglobin within the RBCs. Also, as the storage duration increase there is haemolysis of the oldest red blood cells in the stored blood. This observation is consistent with studies conducted by MI Al Nuaimy [28] and Eze et al. [29] which documented decreases in haemoglobin concentration as storage duration increase. In contrast, similar study conducted by Adias, Moore-Igwe [30] did not find any decreases in Haemoglobin concentration as storage duration increase. The decreases in Hb observed in this study could be attributed to micro-environmental changes during storage. Normally, few RBCs haemolyse under storage conditions unless the RBC membrane becomes compromised. The decrease in haemoglobin concentration is indicative of membrane instability due to the fact that during storage, metabolism activities slow down resulting in reduce ATP and pH concentrations [31, 32]. Reduced pH in RBC metabolic activity reduces the production of 2, 3-DPG, leading to shape change [20, 33]. This leads to the development of a knobbed appearance and progresses into blunt echinocytic projections resulting in ultimate haemolysis [20, 33].

The morphological changes observed on assessment days 0 and 7 are in consonance with the findings of Antwi-Baffour [20] and Bhargava et al. [34] which reported normocytic normochromic RBCs on assessment days 0 and 7. The morphological changes on days 14 and 21 are in contrast with the findings of Antwi-Baffour [20] who reported fairly normocytic cells with few echinocytes on day 14 and few spherocytocytes on day 21. The findings of Bhargava et al. [34] on days 14 and 21 revealed few echinocytes, spherocytes, marked echinocytes which are in contrast with the findings of this study. The morphological changes observed on assessment day 28 were similar to the observations of Bhargava et al. [34] which revealed few normocytes with marked echinocytosis, spherocytocytosis and spherocytosis. The morphological changes observed on assessment days 35 of storage were similar to the findings of Bhargava et al. [34] which reported marked echinocytosis and spherocytosis, but in contrast with the findings of Antwi-Baffour (2015) which reported hypochromasia with rouleaux formation and marked spherocytocytosis.

Morphological assessment of RBCs on the various storage days revealed degenerative changes. The change in the shape of normocytes through echinocyte, spherocytes to spherocytocytes could be attributed to fact that, RBCs depend on only glucose metabolism to generate ATP, so RBCs undergo glycolysis in the enclosed blood bag. As the storage duration increase, the bye product of glycolysis, lactic acid accumulates in the plasma in the blood bag, resulting in acidosis which inhibits glycolysis through a negative feedback mechanism. Adenosine deaminase in stored blood causes the breakdown of adenosine to produce inosine and ammonia. The changes in glycolytic metabolism, coupled with increase in protons reduce the pH of the medium. The reduction in pH leads to a decrease in 2, 3 diphosphoglycerate level. As acid accumulates, glycolytic metabolism slows down, levels of ATP, pH and 2, 3 DPG decline progressively altering the shape of RBCs [35, 36]. ATP is vital to maintaining the RBC membrane and the shape of the RBCs [37, 38]. The depletion of ATP in the blood bag leads to loss of membrane integrity and RBC deformability property (which allows it to meander its way through vessels). This also leads to crenation and spiculation of the RBCs [37, 38].

235 Decrease in ATP production directly relates to spherocytosis of RBCs [39], the reason for the observation
236 of increase spherocytes as storage duration increase. Findings from studies have proven that storage
237 lesions impact the post transfusion viability of RBCs through various mechanisms. During storage,
238 glucose metabolism is altered resulting in the reduction of intracellular glucose, which leads to low ATP
239 production and reduced 2, 3 diphosphoglycerate. These biochemical changes make RBCs prone to
240 oxidative stress, compromising membrane integrity and also cause early haemolysis [40, 41]. Again,
241 RBCs undergo untimely exposure and the activation of elimination or removal signal on the cell
242 membranes, which are similar to the physiological aging antigens. Removal signals when activated could
243 lead to early immune recognition and the removal of RBCs from circulation post transfusion [40, 42]. The
244 optimum reason for transfusion of RBCs is the re-establishment of a medium to carry oxygen to body
245 tissues. It is therefore worth noting that, efficacy of transfusion is evaluated by the survival of the donor
246 RBCs in the recipient [43].
247 Also, the loss of RBC membrane integrity results in increase echinocytes, spherocytes and
248 spheroechinocytes, thus exposes RBCs to enhanced clearance by macrophages of the
249 reticuloendothelial system of the blood recipient [42, 44]. The unique biconcave structure of RBCs is
250 important to perform its function of delivering oxygen to tissues because of its deformability which enables
251 it to traverse capillaries without any obstruction, thus any change in the RBC membrane affects its
252 deformability, leads to circulatory obstruction and would increase RBC clearance post transfusion [45,
253 46].

254 **CONCLUSION**

256 Blood stored in CPDA-1 collection bag at a temperature of $4 \pm 2^\circ\text{C}$ develops lesions during the 35 days
257 storage period. Haemoglobin concentration decreased with increase duration of storage. Again,
258 significant degenerative changes occur in the shape of red cells from normocytic through echinocytes,
259 spheroechinocytes and spherocytes as the storage duration increase. This could increase patients' risk of
260 experiencing post transfusion complications and may not promote the achievement of the expected
261 therapeutic benefits of blood transfusion. The study therefore recommends that, blood with less storage
262 duration should be preferred for transfusion for best therapeutic improvement.

263 **ACKNOWLEDGEMENTS**

265 The authors thank the Medical Laboratory Scientists at the Tamale Teaching Hospital for technical
266 support. They also thank the Biomedical Laboratory Sciences department of the University for
267 Development Studies, Tamale Campus for institutional support.

268 **COMPETING INTERESTS**

270 Authors have declared that no competing interests exist.

271 **AUTHORS' CONTRIBUTIONS**

273 This study was designed and supervised by SBB and LQ. KB and SJR drafted the manuscript. PPD and
274 BG contributed to the draft of the manuscript. KB, SJR and FB participated in the recruitment and
275 sampling of study subjects. MB and YA made financial contributions towards the study and were involved
276 in the laboratory analysis of the samples. MB, CK and KM made contributions to the study design and
277 also helped draft the manuscript. SBB supervised and made intellectual contributions to the manuscript.
278 M.B. participated in subject recruitment. PPD, B.M., YA and L.Q was involved with the statistical analysis.
279 All authors read and approved the final manuscript.

280 **Ethical Approval and Consent:**

282 Ethical clearance was granted by the University for Development Studies, Tamale; and the Research and
283 Ethical Clearance Committee of the Tamale Teaching Hospital. Informed consent was obtained from
284 participant before recruiting them for the study.

285 **REFERENCES**

- 287 1. Prowse, C., et al., *Commercially available blood storage containers*. Vox Sanguinis, 2014. **106**(1):
288 p. 1-13.

- 289 2. Glasier, A., et al., *Sexual and reproductive health: a matter of life and death*. The Lancet, 2006.
290 **368**(9547): p. 1595-1607.
- 291 3. WHO, *Status of blood safety in the WHO Africa region. Report of the 2010 survey*. 2014:
292 Brazzaville.
- 293 4. Choudhury, N., *Blood transfusion in borderless South Asia*. Asian journal of transfusion science,
294 2011. **5**(2): p. 117.
- 295 5. Bloch, E.M., M. Vermeulen, and E. Murphy, *Blood transfusion safety in Africa: a literature review
296 of infectious disease and organizational challenges*. Transfusion medicine reviews, 2012. **26**(2):
297 p. 164-180.
- 298 6. Hult, A., *Towards a detailed understanding of the red blood cell storage lesion: and its
299 consequences for in vivo survival following transfusion*. 2015, Umeå universitet.
- 300 7. Gupta, P., et al., *TO STUDY THE MORPHOLOGICAL CHANGES SEEN IN STORED BLOOD IN A
301 BLOOD BANK*. JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS, 2016.
302 **5**(77): p. 5705-5709.
- 303 8. Kim-Shapiro, D.B., J. Lee, and M.T. Gladwin, *Storage lesion: role of red blood cell breakdown*.
304 Transfusion, 2011. **51**(4): p. 844-851.
- 305 9. Obrador, R., S. Musulin, and B. Hansen, *Red blood cell storage lesion*. Journal of veterinary
306 emergency and critical care, 2015. **25**(2): p. 187-199.
- 307 10. Yoshida, T., M. Prudent, and A. D'Alessandro, *Red blood cell storage lesion: causes and potential
308 clinical consequences*. Blood Transfusion, 2019. **17**(1): p. 27.
- 309 11. Tzounakas, V.L., et al., *Donor variation effect on red blood cell storage lesion: a multivariable, yet
310 consistent, story*. Transfusion, 2016. **56**(6): p. 1274-1286.
- 311 12. Mustafa, I., et al., *Time dependent assessment of morphological changes: leukodepleted packed
312 red blood cells stored in SAGM*. BioMed Research International, 2016. **2016**.
- 313 13. Koch, C.G., et al., *Duration of red-cell storage and complications after cardiac surgery*. New
314 England Journal of Medicine, 2008. **358**(12): p. 1229-1239.
- 315 14. Orlov, D. and K. Karkouti, *The pathophysiology and consequences of red blood cell storage*.
316 Anaesthesia, 2015. **70**: p. 29-e12.
- 317 15. Osaro, E., et al., *A review of the pathophysiology and consequences of red cell storage-fresh
318 versus stored red cells-implication for optimum use of scarce allogenic blood*. American
319 Association for Science and Technology Journal of Medicine, 2018. **4**(2): p. 32-50.
- 320 16. Vani, R., et al., *Storage lesions in blood components*. blood, 2015. **6**: p. 7.
- 321 17. Gómez-Simón, A., et al., *Evaluation of four rapid methods for hemoglobin screening of whole
322 blood donors in mobile collection settings*. Transfusion and Apheresis Science, 2007. **36**(3): p.
323 235-242.
- 324 18. Heath, K.V., et al., *Antiretroviral treatment patterns and incident HIV-associated morphologic
325 and lipid abnormalities in a population-based cohort*. J Acquir Immune Defic Syndr, 2002. **30**(4): p.
326 440-7.
- 327 19. WHO, *Blood donor selection: guidelines on assessing donor suitability for blood donation*. 2012:
328 World Health Organization.
- 329 20. Antwi-Baffour, S., *Prolonged Storage of Red Blood Cells for Transfusion in Citrate Phosphate
330 Dextrose Adenine-1 Affects Their Viability*. Open Access Library Journal, 2015. **2**(09): p. 1.
- 331 21. Trouern-Trend, J.J., et al., *A case-controlled multicenter study of vasovagal reactions in blood
332 donors: influence of sex, age, donation status, weight, blood pressure, and pulse*. Transfusion,
333 1999. **39**(3): p. 316-320.
- 334 22. Newman, B., et al., *Donor reactions in high-school donors: the effects of sex, weight, and
335 collection volume*. Transfusion, 2006. **46**(2): p. 284-288.

- 336 23. Petrie, H.J., E.A. Stover, and C.A. Horswill, *Nutritional concerns for the child and adolescent*
337 *competitor*. Nutrition, 2004. **20**(7-8): p. 620-631.
- 338 24. Spear, B.A., *Adolescent growth and development*. Journal of the American Dietetic Association,
339 2002. **102**(3): p. S23-S29.
- 340 25. Christian, P. and E.R. Smith, *Adolescent undernutrition: global burden, physiology, and*
341 *nutritional risks*. Annals of Nutrition and Metabolism, 2018. **72**(4): p. 316-328.
- 342 26. Pavord, S., et al., *UK guidelines on the management of iron deficiency in pregnancy*. British
343 journal of haematology, 2012. **156**(5): p. 588-600.
- 344 27. Salvin, H.E., et al., *Iron deficiency in blood donors: a national cross-sectional study*. Transfusion,
345 2014. **54**(10): p. 2434-2444.
- 346 28. MI Al Nuaimy, K., *Haematological Changes in Stored Blood*. JOURNAL OF EDUCATION AND
347 SCIENCE, 2008. **21**(4): p. 49-56.
- 348 29. Eze, E.M., et al., *Changes in Plasma Haemoglobin Concentration in Citrate Phosphate Dextrose*
349 *Adenine-1 (CPDA-1) Stored Blood*. 2019.
- 350 30. Adias, T., B. Moore-Igwe, and Z. Jeremiah, *Storage related haematological and biochemical*
351 *changes of CPDA-1 whole blood in a resource limited setting*. Journal of Blood Disorders &
352 Transfusion, 2012. **3**(3): p. 124.
- 353 31. Tinmouth, A. and I. Chin-Yee, *The clinical consequences of the red cell storage lesion*. Transfusion
354 Medicine Reviews, 2001. **15**(2): p. 91-107.
- 355 32. Chin-Yee, I., N. Arya, and M.S. d'Almeida, *The red cell storage lesion and its implication for*
356 *transfusion*. Transfusion science, 1997. **18**(3): p. 447-458.
- 357 33. Shohet, S. and J. Haley, *Red cell membrane shape and stability: relation to cell lipid renewal*
358 *pathways and cell ATP*, in *Red Cell Shape*. 1973, Springer. p. 41-50.
- 359 34. Bhargava, P., R. Gupta, and V. Khare, *Cpda-1 stored blood induced effect on hematological and*
360 *biochemical parameter up to 28 days*. Rec Adv Path Lab Med, 2016. **2**(3&4): p. 8-12.
- 361 35. Hess, J.R., *Red cell changes during storage*. Transfusion and Apheresis Science, 2010. **43**(1): p.
362 51-59.
- 363 36. Adams, F., et al., *Biochemical storage lesions occurring in nonirradiated and irradiated red blood*
364 *cells: a brief review*. BioMed research international, 2015. **2015**.
- 365 37. Park, Y., et al., *Metabolic remodeling of the human red blood cell membrane*. Proceedings of the
366 National Academy of Sciences, 2010. **107**(4): p. 1289-1294.
- 367 38. Gov, N. and S. Safran, *Red blood cell membrane fluctuations and shape controlled by ATP-*
368 *induced cytoskeletal defects*. Biophysical journal, 2005. **88**(3): p. 1859-1874.
- 369 39. Girasole, M., et al., *The how, when, and why of the aging signals appearing on the human*
370 *erythrocyte membrane: an atomic force microscopy study of surface roughness*. Nanomedicine:
371 Nanotechnology, Biology and Medicine, 2010. **6**(6): p. 760-768.
- 372 40. Reisz, J.A., et al., *Oxidative modifications of glyceraldehyde 3-phosphate dehydrogenase regulate*
373 *metabolic reprogramming of stored red blood cells*. Blood, The Journal of the American Society
374 of Hematology, 2016. **128**(12): p. e32-e42.
- 375 41. Pallotta, V., et al., *Storing red blood cells with vitamin C and N-acetylcysteine prevents oxidative*
376 *stress-related lesions: a metabolomics overview*. Blood Transfusion, 2014. **12**(3): p. 376.
- 377 42. D'Alessandro, A., et al., *An update on red blood cell storage lesions, as gleaned through*
378 *biochemistry and omics technologies*. Transfusion, 2015. **55**(1): p. 205-219.
- 379 43. Bunn, H.F., et al., *Hemoglobin function in stored blood*. The Journal of clinical investigation,
380 1969. **48**(2): p. 311-321.
- 381 44. Vittori, D., D. Vota, and A. Nesse, *Erythrocyte: programmed cell death*, in *Anemia*. 2012, Intech.
- 382 45. Hosseini, S.M. and J.J. Feng, *A particle-based model for the transport of erythrocytes in*
383 *capillaries*. Chemical engineering science, 2009. **64**(22): p. 4488-4497.

384 46. Yedgar, S., A. Koshkaryev, and G. Barshtein, *The red blood cell in vascular occlusion*.
385 Pathophysiology of haemostasis and thrombosis, 2002. **32**(5-6): p. 263-268.
386